CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
lisocabtagene maraleucel 治疗 Richter 转化——病例系列
英文原题：Lisocabtagene Maraleucel for Richter's Transformation-A Case Series.
查看英文原题
Lisocabtagene Maraleucel for Richter's Transformation-A Case Series.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
这一系列真实病例提示，liso-cel 联合 ibrutinib 可能是治疗 RT 的一种有前景的方案，值得进一步探索。
研究思路结论见上方概要
背景
Richter转化（RT）从慢性淋巴细胞白血病（CLL）向淋巴瘤转化预后不良。本病例系列研究了lisocabtagene maraleucel（liso-cel）在6例RT患者中的疗效，重点探讨了同时使用ibrutinib治疗的影响。
方法
本单中心病例系列纳入了6例接受liso-cel治疗的RT患者。收集了与疗效、安全性、CAR-T 扩增动力学和可测量残留病相关的临床数据。
结果
最佳总体缓解率为83.3%。接受ibrutinib与liso-cel同步治疗的四名患者至今仍显示MRD阴性完全缓解。无人经历严重（3级及以上）细胞因子释放综合征，而1人出现严重（3级及以上）免疫效应细胞相关神经毒性综合征（ICANS）。所有患者均观察到体内CAR扩增。
展开英文摘要原文
METHODS
Six patients were with RT who received liso-cel from were included in this single institution case series. Clinical data related to efficacy, safety, CAR-T expansion kinetics, and measurable residual disease were collected.
RESULTS
The best overall response was 83.3%. The four patients who received ibrutinib concurrent with liso-cel therapy continue to show MRD-negative complete response till date. None experienced severe (grade 3+) cytokine release syndrome while 1 had severe (grade 3+) immune-effector cell-associated neurotoxicity syndrome (ICANS). All patients were noted to have in vivo CAR expansion.
CONCLUSION
This series of real cases suggests liso-cel with concurrent ibrutinib may be a promising treatment for RT, warranting further exploration.
论文信息
- 作者
- Smith CJ、Goyal A、Smith BR、Lee D、Jensen A、Alexander J、Smith M、Frank M
- 单位
- Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University School of Medicine Stanford California USA.United States
- 期刊
- EJHaem2025 Apr
- 原文标识
- PubMed 40066130 · DOI 10.1002/jha2.70011
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →